On Thursday, Renishaw plc, a global provider of manufacturing technologies, analytical instruments, and medical devices, reported a revenue increase of 6% to £173.9m for the three months ending September 30, 2024. This compares to £164.5m in the same period the previous year. The company also saw a 22% rise in both adjusted and statutory profit before tax, reaching £34.0m up from £28.0m.
The Americas and EMEA regions experienced heightened demand, contributing to the revenue growth. However, the Asia-Pacific (APAC) region saw a decline compared to the previous year, which had been bolstered by consumer electronics sector orders. Despite a mixed trading environment, the company managed to achieve solid growth.
The manufacturing technologies sector of Renishaw's business witnessed a 7% revenue increase to £167.5m, driven by strong sales of position encoders to the semiconductor manufacturing sector. The additive manufacturing products also showed robust growth, benefiting from a healthy order book carried into FY2025. Nonetheless, industrial metrology product demand declined due to strong sales in the prior period to the consumer electronics sector in APAC.
Conversely, the analytical instruments and medical devices segment experienced a downturn, with revenue falling 16% to £6.4m, mainly due to the timing of sales for spectroscopy products.
Renishaw's financial position remains robust, with net cash and cash equivalents, and bank deposit balances totaling £276.1m as of September 30, 2024, an increase from £217.8m on June 30, 2024.
Looking ahead, Renishaw remains cautious about the demand from the semiconductor manufacturing sector for the rest of FY2025. Despite this, the company is pursuing various growth opportunities and expects solid overall revenue growth in line with the Board's expectations. Renishaw also continues to focus on managing costs and improving productivity to advance towards its margin goals. The results for the half year ending December 31, 2024, will be announced on February 13, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.